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Abstract
Background: Sorafenib is a multikinase inhibitor with antiangiogenic and antiproliferative properties,
approved for the treatment of hepatocellular carcinoma. The effect of Sorafenib on liver regeneration in
healthy rats was investigated.
Methods: Sixty Wistar rats received either Sorafenib (group S; 15 mg/kg) or placebo for 14 days prior to
resection and until sacrifice. After a 70% partial hepatectomy, the rats were euthanized on post-operative
days (POD) 2, 4 or 8. Hepatocyte proliferation was estimated by immunohistochemistry for Ki-67 antigen
using stereological methods on sections prepared by systematic uniform random sampling.
Results: Seven animals (12%) died after surgery. Death rates were similar in treated rats and controls.
At hepatectomy, the body weight was significantly lower in group S rats. The liver weight and regeneration
rates were lower in group S rats on PODs 2, 4 and 8. Hepatocyte proliferation was significantly lower in
group S animals on PODs 2 and 4. Alanine aminotransferase ALAT was significantly higher in the
Sorafenib-treated group on PODs 2, 4 and 8. Alkaline phosphatase ALP and bilirubin levels were similar
in the two groups, although bilirubin was elevated in group S rats on POD 8.
Conclusion: In this rat model, Sorafenib did not increase post-hepatectomy mortality, but was associ-
ated with a significant impaired liver weight gain, regeneration rates and hepatocyte proliferation.
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Introduction
The liver is characterized by complex physiology and the ability to
undergo rapid regeneration.1–3 Documented evolutionary pres-
sures have driven these unique traits, and have resulted in a phe-
nomenal ability to recover lost functional capacity without
jeopardising the viability of the entire organism.
Hepatocellular carcinoma (HCC) is the sixth most common
cancer worldwide and the third most common cause of cancer-
related death.4 At present, local ablation of small tumours, surgical
resection or transplantation offer the best chances of a cure.5
Sorafenib is an orally active multikinase inhibitor with antian-
giogenic and antiproliferative properties, which has been shown
to improve the survival of patients with preserved liver function
and advanced HCC.6,7 Sorafenib is approved for the treatment of
advanced HCC in the USA and Europe.8 Against this back-
ground, Sorafenib use may be considered in other patients with
HCC as an adjuvant or neoadjuvant therapy. In addition, Soraf-
enib treatment is increasingly being used in patients who, after a
proper work-up, are candidates for local treatment, i.e. surgery or
local ablation.
Liver regeneration is dependent on neoangiogenesis and tissue
proliferation. Inhibition of these vital processes by Sorafenib
could impair regeneration. The aim of the present study was to
investigate how treatment with Sorafenib influences liver regen-
eration in healthy rats, after a partial hepatectomy. Unlike previ-
ous studies of experimental liver regeneration after a hepatectomy,
design-based stereological methods to provide accurate estimates
of hepatocyte proliferation were used.
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Material and methods
All animal experiments were performed under the approval of the
Danish Animal Experiment Inspectorate, Copenhagen, Denmark,
under license number 2009/561–1752 and in accordance with the
‘Guide for the Care and Use of Laboratory Animals’ published by
the US National Institutes of Health. Animals were housed in
standard animal laboratories at a controlled temperature of 23 °C,
with an artificial 12-h light-dark cycle and free access to food and
water.
Sixty Wistar rats were randomly divided into two groups, and
received either Sorafenib (group S) or placebo saline (control
group P). All animals were dosed by oral gavage. Sorafenib was
prepared by dissolving a 200-mg Sorafenib tablet in 40 ml of
saline, in a sealed bottle 15 min prior to gavage (final concentra-
tion 5 mg/ml). The solution was maintained under constant stir-
ring on an automatic laboratory mixer. Rats in group S were given
15 mg of Sorafenib per kg per day. Rats in group P were given an
equivalent volume of 0.75 ml of saline. The rats were awake and
not anaesthetized during gavage, which was performed by an
experienced professional animal caretaker. All animals were given
treatment (S or P) every day from 2 weeks prior to resection and
until sacrifice on post-operative days (POD) 2, 4 or 8. The animals
were treated on the day of resection and on the day of sacrifice as
well. On both days, oral gavage was given 1 h prior to resection/
sacrifice.
After 14 days of treatment, the rats underwent a 70% partial
hepatectomy. All surgical procedures were performed under inha-
lation anaesthesia. Induction was performed in a glass cylinder
through which a mixture of oxygen (2.0 l/min), nitrous oxide,
(0.5 l/min) and 4% isoflurane (Forene; Abbott Laboratories,
Maidenhead, UK) was blown. During surgery, anaesthesia was
maintained with 2% isoflurane, oxygen and nitrous oxide as
above, administered through a nasal mask. With the animal placed
in a supine position on a heated pad, a transverse abdominal
incision was made and the liver was mobilized. A partial liver
resection was performed by a previously described technique.9
Briefly, the base of the median and left lateral lobes was ligated,
and the lobes were resected, resulting in a 70% liver resection
model. The abdomen was closed with a 4–0 absorbent suture in
two layers, single knots. Before surgery, the animals received a
subcutaneous injection of a long-lasting non-steroidal anti-
inflammatory, 5 mg/kg Carprofen (Rimadyl; Pfizer Animal
Health, Exton, PA, USA) and 1.0 ml of isotonic saline. The rats
were kept in the animal facilities until the end of the experiment.
After a partial hepatectomy, rats were block randomized into 3
groups of 10 (plus 3 groups of 10 for controls), for evaluation on
the same POD. Thus, the animals in groups 1, 2 and 3 were
analysed on PODs 2, 4 and 8, respectively. On the given POD, the
rats were again weighed and anaesthetized, and a laparotomy was
performed through the previous incision. Blood samples were
collected from the heart by cannulation. All rats were subse-
quently euthanized by cervical dislocation. The regenerated liver
was then mobilized and removed. The liver weight was recorded,
and the caudate lobe was removed, weighed and fixed in
phosphate-buffered 4% formaldehyde for 24–48 h. Body weight,
morbidity and mortality, was recorded daily throughout the study
period. Dead rats were autopsied to establish the cause of death.
Biochemical analysis
Blood was sampled from the heart at euthanization, processed and
stored at -80°C until analysis. Alanine aminotransferase (ALAT),
alkaline phosphatase (ALP) and bilirubin (BR) levels were meas-
ured using the Modular P (Roche Diagnostics, Mannheim,
Germany).
Liver weight and regeneration rate
The total liver weight prior to a partial hepatectomy was calcu-
lated from the resected liver weight.9 The post-operative total liver
weight was measured at sacrifice. The change in liver weight was
recorded as the hepatic regeneration rate (RR). RR is defined
as (liver weight per 100 g of the body weight at sacrifice/pre-
operative projected liver weight per 100 g of the body weight) ¥
100:
RR LWm g LWp g= ( ) ( )( )×100 100 100
LWm is the measured liver weight at sacrifice; LWp is the pre-
operative projected liver weight.
Immunohistochemistry
Hepatocellular proliferation was estimated using immunohisto-
chemical staining for the Ki-67 antigen. Ki-67 is expressed during
all active phases of the cell cycle (G1, S, G2 and M phases), but not
in resting (G0) cells.10 Sections for immunohistochemistry were
prepared according to stereological principles using systematic
uniform random sampling (SURS; see Stereological quantita-
tion). Immunohistochemical staining of the thick 30-mm paraffin
sections was performed using a standard (in-house) protocol,
modified for use in thick sections. Briefly, sections were deparaffi-
nized and boiled in a microwave oven in Tris-EGTA buffer, pH 9
for heat-induced epitope retrieval. Monoclonal mouse anti-rat
Ki-67 specific antibody (clone MIB-5, isotype IgG1; Dako, Glos-
trup, Denmark)11 diluted at 1:20 was used as the primary antibody
in this study. Sections were incubated with the primary antibody
for 4 days at 4°C. Sections were washed, positive signals were
visualized using the EnVision+ horseradish peroxidase labelled
anti-mouse detection system (Dako), and the sections were coun-
terstained with haematoxylin.
Stereological quantitation
The formaldehyde-fixed caudate lobe was cut into 2-mm-thick
parallel slabs using a tissue slicer and handled as described previ-
ously, before paraffin embedding.12 A 30-mm section was cut from
each of the paraffin-embedded blocks creating a set of SURS
sections for immunostaining and further analysis.13,14
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All sections were analysed using the Olympus BH-50 micro-
scope, modified for stereology with a motorized stage and a digital
camera connected to a PC with newCAST 3.6.5.0 software (Visi-
opharm, Hørsholm, Denmark). The same investigator analysed all
sections and was blinded to the section group.
The optical fractionator method was used to estimate the total
number of Ki-67 positive cells in each section, as shown in
Fig. 1a,b. Microscopy was performed using a 60¥ oil objective
lens. Approximately 0.5%, of the section area, was analysed for
Ki-67 positive cells and the thickness of the sampled section was
measured every time a positive cell was seen in the frame. The
number of Ki-67-positive cells N was calculated using the follow-
ing formula:
N
SSF ASF HSF
Q= × × ×∑1 1 1
SSF is the Section Sampling Fraction = a(frame)/(dx ¥ dy),
a(frame) is the area of the 2D unbiased counting frame, 7500 mm2,
and dx and dy are the stepping distance in the x- and y-direction
equal to 1225 mm, respectively.
ASF is the Area Sampling Fraction = h/tq-,15 where h is the
disector height (15 mm) and tq- is the q- weighted section thick-
ness (=15/28.54).
HSF is the Height Sampling Fraction = the height of the
sampled section cut on a calibrated microtome divided by
the average thickness of the embedded slabs after shrinkage. The
thickness of the slabs was 2 mm before embedding. Several of
these were exhaustively cut in thin histological slices for measur-
ing slab thickness after shrinkage. Seven tissue land markers for
these slabs were followed through the whole series of sections and
the average slab thickness after shrinkage calculated:
1510 1570 1585 2005 2080 1885 1850 7
1784
+ + + + + +( )
=
μ
μ
m
m
and Q- is the number of positive cells counted. The counting rules
used are described in Fig. 1a,b.
Statistical analysis
Data are presented as the mean [standard error of the mean
(SEM)]. For comparison of the two groups, the t-test was used
where applicable, i.e. when normality and equal variance tests
were passed. When the t-test was not applicable, a Mann-Whitney
Rank Sum test was used, e.g. in following cases: BW-POD 2,
ALAT-POD 8, ALP-POD 8, BR-POD 2, BR-POD 4 and Ki67-POD
8.
The reproducibility of the stereological data was tested by
re-evaluation of all sections from eight randomly chosen livers.
Data from the first (A1) and second evaluations (A2) were com-
pared using the Mann–Whitney Rank sum test. Finally, the vari-
ability between readings was assessed by difference-average plots,
as described by Bland and Altman16
a
b
Figure 1 Kasper Jarlhelt Andersen: Ki-67-stained liver sections with
the counting frames displayed. A positive hepatocyte was counted if
it was significantly stained according to a trained histologist, and if
the cell was sampled by the optical fractionator. The disector height
was 15 mm and it was placed in the middle of the thick section (cut
section thickness was 30 mm and it was approximately 27 mm after
shrinkage measured at the microscope). Positive-stained cells in
focus at the start of the disector were not counted but all positive-
stained hepatocytes coming into focus in the next 15 mm were
counted, if they were sampled by the counting frame. Cells were
sampled by the counting frame, if they were inside the counting
frame, did touch the inclusion lines and did not touch the exclusion
lines. The red lines (left and bottom) are exclusion lines and green
lines (top and right) are inclusion lines. (a) Counting frame 100 ¥
75 mm. No Ki-67 positive hepatocytes are observed in the frame. (b)
Counting frame 100 ¥ 75 mm. Three Ki-67 positive hepatocytes
marked with ‘A's’, are observed inside the frame
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Results
Mortality and morbidity
Seven animals died prior to evaluation, four as a consequence of
suture gnawing, resulting in intestinal perforation and three from
unidentifiable causes. Of these seven animals, three were from
group S and four were from group P. All other rats were healthy
and behaved as expected with regard to activity and food
consumption.
Liver biochemistry
Alanine aminotransferase
High concentrations of ALAT were observed during the early part
of the post-operative period, with a level on POD 2 of 438 U/l for
group S and 179 U/l for group P rats. Concentrations rapidly
decreased during the following days, before reaching low values
on POD 4. Group S rats had significantly higher ALAT concen-
trations during the regenerative/recovery period (P < 0.001), the
most distinct difference being 259 U/l g on POD 2 (Fig. 2a).
Bilirubin
High concentrations of BR were observed during the early part of
the post-operative period, with levels on POD 2 of 4.2 umol/l and
3.1 umol/l for group S and group P rats, respectively. Concentra-
tions decreased during the following days, reaching low levels on
POD 8. No difference was found comparing BR in the two groups
on PODs 2 and 4. However, group S rats had a significantly higher
BR concentration (P < 0.001) of 1.0 umol/l on POD 8 (Fig. 2b).
Alkaline phosphatase
High concentrations of ALP were also seen early on in the post-
operative period with levels on POD 2 of 345 U/l and 353 U/l for
group S and group P rats, respectively. No significant difference in
ALP levels was found when you compare the two groups over the
course of the study period (Fig. 2c).
Body weight
At the start of oral gavage, animals had a mean body weight of
225 g (209–255). At the time of resection, the mean body weight
was 264 g (236–279) for group S and 284 g (246–322) for group P
rats, respectively. Weight loss was noted during the first four
PODs, after which weight gain was observed in group P, but not in
group S animals. There was a statistical significant difference in
bodyweight, comparing group S and group P rats before resection
(P < 0.001) and on POD 4 (P = 0.025) and POD 8 (P < 0.001)
(Fig. 3).
Liver weight
The mean weight of the resected 70% liver in group S rats was
5.8 g (4.4–6.9), giving an estimated median total liver weight
(100%) of 8.3 g (6.3–9.9) in this group. For group P rats, the mean
weight of the resected 70% liver was 7.0 g (5.3–8.1), giving an
estimated median total liver weight (100%) of 10.0 g (7.6–11.6).
a
b
c
Figure 2 Kasper Jarlhelt Andersen: the mean alanine aminotrans-
ferase (a), bilirubin (b) and alkaline phosphatase (c) [standard error
(SE)] for each group of animals. Blue circles illustrate Sorafenib and
red triangles illustrate placebo
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Gains in liver weight during the recovery/regenerative period for
each group are shown in Fig. 4. Major growth was noted during
PODs 0–4 for both groups, although this was particularly evident
in group P. The liver weight in group P rats was close to the
baseline on POD 8, whereas the pre-operative liver weight in
group S rats was not reached by this time. Group S animals had a
significantly lower liver weight at all times after a hepatectomy
until the end of experiment (P < 0.001), with the most distinct
differences of 3.0 g and 2.9 g being seen on PODs 4 and 8, respec-
tively (Fig. 4a).
Liver regeneration rate
RR showed similar patterns to those seen in the liver weight curves
(Fig. 4b), i.e. with most accelerated regrowth taking place during
PODs 0–4, although the RR curves were more stable and showed
less variation on each POD than did the liver weight curves. For
group P rats, a RR of 89 was reached at POD 8, by which point the
RR for the group S animals was 82. Group S rats had a significantly
lower RR during the whole post-operative period.
Hepatocyte proliferation
Proliferation was maximal on PODs 2 and 4 in both groups, after
which there was a decline to low levels on POD 8. Proliferation
was significantly lower in group S compared with group P rats on
PODs 2 and POD 4 (Fig. 5).
Discussion
Liver regeneration depends on hepatocyte proliferation and
neoangiogenesis. Interference with either of these vital processes
by Sorafenib could impair or delay regeneration.
The effect of Sorafenib treatment on liver regeneration in
healthy rats after a partial hepatectomy was studied. We chose to
treat the animals both before and after resection to study the full
impact of Sorafenib on liver regeneration. Sorafenib was admin-
istered at a dose of 15 mg/kg/day in order to match the human
dose.17 Body weight dynamics are a reliable marker of acute stress
in animals and as such are crucial to studying liver resections.18 It
was found that rats in the Sorafenib group had a significantly
lower mean body weight at the time of liver resection (Fig. 3). As
Figure 3 Kasper Jarlhelt Andersen: the mean body weight [stand-
ard error (SE)] for each group of animals. Blue circles illustrate
Sorafenib and red triangles illustrate placebo. POD, post-operative
day
a
b
Figure 4 Kasper Jarlhelt Andersen: the mean liver weight (a) and
regeneration rate [standard error (SE)] for each group of animals.
Blue circles illustrate Sorafenib and red triangles illustrate placebo.
POD, post-operative day
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animals had similar body weights before starting oral gavage, this
suggests an anorectic effect of Sorafenib. Furthermore, rats in
both groups S and P lost weight until POD 4, after which a steep
increase in body weight was observed in the control group P rats,
but not in the group S-treated rats.
ALAT, ALP and BR have been traditionally used as markers of
hepatic injury. In particular, ALAT is used as a measure of the
degree of liver cell damage.19 We found initially high concentra-
tions of ALAT in both treated and control groups of animals on
POD 2, presumably reflecting liver injury after resection, before
ALAT fell to low levels on PODs 4 and 8. However, significantly
higher ALAT concentrations were seen in the group S rats
throughout the study, suggesting a more severe degree of liver
damage in the treated animals.
Bilirubin and ALP were elevated in both groups on POD 2,
falling to low levels at POD 4. No differences were seen in these
markers, comparing Sorafenib and placebo-treated animals. This
suggests that Sorafenib does not damage the biliary tree in the
early phase after a resection. Bilirubin was significantly elevated in
the Sorafenib-treated group on POD 8, whereas no difference was
found with regard to ALP. This is difficult to explain and may be a
chance finding, as one would expect eventual differences to be
observed in both parameters if present, reflecting damage to the
biliary tree caused by Sorafenib.
Steep increases were found in liver weight from PODs 0 to 4.
These rises continued, with a less steep incline, to POD 8. Values
for liver weight were significantly lower in the Sorafenib-treated
animals at all time points. After correcting for bodyweight, a
similar pattern was found to apply when estimating liver RR.
Thus, the impaired regenerating capacity of the liver in treated
animals cannot be ascribed to an anorectic effect of Sorafenib, at
least not as the sole factor. Probably inhibition of liver growth was
caused by Sorafenib’s anti-angiogenetic and anti-proliferative
properties acting directly on the liver during regeneration. In a
study by Hora et al. on mice treated with Sorafenib for 14 days
before resection and until sacrifice and in mice treated after resec-
tion and until sacrifice, differences in liver regeneration were not
found when comparing treated animals and controls after 24 h
and 72 h.20 On the other hand, Hora et al.20 found a significantly
lower liver regeneration in Sorafenib treated animals after 120 h.
These results partly differ from those of the present study where
we found a significant difference in liver regeneration judged by
regeneration rate POD 2. One explanation could be that rats are
more sensitive to the effects of Sorafenib than mice. This is sup-
ported by a recent study by Kurniali et al. 21on Sorafenib-treated
liver-resected mice where they found no difference in liver regen-
eration when comparing Sorafenib-treated animals and controls
in spite of a high dosage up to 90 mg/kg/day.
In accordance with the liver weight and RR dynamics, we
found high levels of hepatocyte proliferation from PODs 2 to 4 in
both the placebo- and Sorafenib-treated groups, after which they
fell to near zero on POD 8. At all time points, the proliferation
was significantly lower in rats treated with Sorafenib compared
with placebo. Again, this could be explained by Sorafenibs anti-
angiogenetic and anti-proliferative properties acting directly on
the liver during regeneration. Hora et al.20 evaluated cell prolif-
eration by BrdU incorporation. With regard to this parameter
there is agreement between our studies. They found a significant
reduction in cell proliferation after 24 and 72 h in animals
treated with Sorafenib before and after surgery. However, Kur-
niali et al. 21 found no difference in cell proliferation between
Sorafenib-treated mice and controls. One explanation to this dis-
crepancy could be the fact that they estimated cell proliferation
by flow cytometry in contrast to the study by Hora et al. 20 and
the present study, where cell proliferation was judged in histo-
logical sections.
The difference in sensitivity to the effects of Sorafenib demon-
strated between such closely related species such as rats and mice
when comparing the present study to the studies by Hora et al.
and Kurniali et al. clearly demonstrates, that one should be very
cautious when extrapolating these results into humans.
Most previous histopathological studies evaluating hepatic
injury or liver regeneration have used either standard pathological
examination or modified scoring systems such as that described
by Suzuki et al. 22 Routine histopathological examination of a
limited random tissue sample has several drawbacks. Thus, it is
prone to subjectivity, being highly dependent on the observer and
has no component of systematic unbiased randomization. Fur-
thermore, traditional methods of analysis produce at best only
semi-quantitative data, making it more difficult to make statistical
comparisons. In addition, semi-quantitative methods do not
allow for the reference area or volume to be accurately estimated
and as a result, run the risk of a highly biased conclusion. These
Figure 5 Kasper Jarlhelt Andersen: the mean hepatocyte prolifera-
tion (SE) for each group of animals. The 106 is the total number of
positive cells in the liver lobe. Blue circles illustrate Sorafenib and red
triangles illustrate placebo. POD, post-operative day
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pitfalls were avoided by applying stereological methods to select
and evaluate immunohistochemically stained fields in a design-
based randomized manner, in order to estimate the total number
of Ki-67 positive cells in our tissue sections.
In conclusion, Sorafenib does not increase mortality after a
partial hepatectomy in this rat model. However, Sorafenib admin-
istered before and after a liver resection, significantly impairs liver
weight gain, liver regeneration rates and hepatocyte proliferation
as estimated by design-based stereological methods.
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